MedTrace Logo

Microbiome of Depression & Treatment Response to Citalopram

NCT02330068 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2018-03-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility of developing a microbiome probe of depression and to evaluate the microbiome change in a preliminary analysis of treatment response (n=20) vs. non response (n=20) to the antidepressant citalopram. This study is a 12 week open trial that will enroll approximately 80 participants (anticipated 40 study completers with paired biomarker data) with an episode of major depression, Bipolar I or Bipolar II and 40 age- and sex-matched healthy controls.

Conditions

  • Major Depressive Disorder, Bipolar I and Bipolar II

Interventions

DRUG

citalopram

Cases

Sponsors & Collaborators

Principal Investigators

  • William Bobo, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02330068 on ClinicalTrials.gov